Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742417 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
A Phase 2 study, sponsored by Instituto Grifols, S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00742417 is a Phase 2 study that has completed, run by Instituto Grifols, S.A.. The registered enrollment target is 42 participants.
The verdict
NCT00742417, a Phase 2 study, has completed, sponsored by Instituto Grifols, S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
Interventions
- OTHER Control
- BIOLOGICAL Albutein 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742417
The ClinicalTrials.gov registry entry for NCT00742417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instituto Grifols, S.A., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT00742417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00742417 about?
NCT00742417 is a clinical study titled "Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid". The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
What is the current status of trial NCT00742417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2007-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00742417?
The interventions under investigation include: Control (OTHER), Albutein 5% (BIOLOGICAL).
Who is sponsoring clinical trial NCT00742417?
This trial is sponsored by Instituto Grifols, S.A., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.